

6<sup>th</sup>

# Swiss Cancer Institute Translational Urogenital Cancer Network Meeting

taking place during the Semi-Annual Meeting Spring

**June 18–19, 2026**

Trafo Congress Center  
Brown Boveri Platz 1, 5400 Baden AG

Scientific Committee

- Dr. Clémentine Le Magnen
- Dr. med. Mohamed Shelan
- Prof. Dr. med. Jean-Philippe Theurillat
- PD Dr. med. Petros Tsantoulis

---

Featuring two keynote lectures by leading experts during the abstract presentations:

**Gert Attard, MD, PhD,**  
UCL Cancer Institute, UK

**Karim Fizazi, MD, PhD,**  
University of Paris Saclay and  
Centre Oscar Lambret, France

Abstract presentations  
each 10min. + 5min.  
discussion time

Credits will be  
requested: SGMO,  
SGU, SRO

# Agenda

## Thursday, June 18, 2026

18:00 – 18:10	Welcome	Prof. Dr. med. J-P. Theurillat
18:10 – 18:40	Key Note Lecture	Karim Fizazi, MD, PhD
18:40 – 18:55	SIESTA-PRISM Substudy: Profiling Risk and underlying mechanisms of sleep disturbances with serum biomarkers in prostate cancer	Dr. med. Martino Pedrani
18:55 – 19:10	Dissecting Immunological Mechanisms driving pathological complete Responses in SAKK 06/19 BCG-Augmented Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer	Victor Le Gall, PhD candidate
Afterwards	Networking Dinner	All

## Friday, June 19, 2026

09:15 – 09:20	Welcome	Dr. C. Le Magnen
09:20 – 09:50	Key Note Lecture	Gert Attard, MD, PhD
09:50 – 10:05	MYC-Driven Microenvironmental Signatures of Liver-Tropic Prostate Cancer: Translation into a Clinical Immunohistochemistry Assay for Risk Stratification	Dr. Alekhya Mazumdar
10:05 – 10:20	Artificial intelligence-based model for predicting treatment response on urine cytology samples in bladder cancer patients undergoing Bacillus Calmette-Guérin therapy: A pilot study	PD Dr. med. Tatjana Vljajnic
10:20 – 10:30	Flash Talks	
10:30 – 11:00	Coffee Break	
11:00 – 11:15	Development of an IHC-based assay to support clinical translation of ERG-K362me-targeted therapy	Dr. Concetta Guerra
11:15 – 11:30	Loss of MTAP Expression and Survival in Patients with advanced Urothelial Carcinoma treated with Enfortumab Vedotin – A retrospective biomarker study	Dr. med. Andreas Michael Schmitt
11:30 – 11:40	Evaluation by the Scientific Committee	
11:40 – 12:15	Wrap-up and Award Ceremony	All



Interested to attend this meeting?  
Scan or click the QR code to register

Swiss Cancer Institute, [events@swisscancerinstitute.ch](mailto:events@swisscancerinstitute.ch)

